Targeted Therapies in Lung Cancer

Overview

Journal Surg Pathol Clin

Publisher Elsevier

Specialty General Surgery

Date 2010 Aug 4

PMID 20680095

Citations 8

Authors

Lucian R Chirieac

Sanja Dacic

Affiliations

Soon will be listed here.

Abstract

An ongoing research and multiple clinical trials involve new targeted therapies and less aggressive treatment regimens that improve survival in patients with lung cancer. Targeted therapeutic agents are based on the concept of discovering genetic alterations and the signaling pathways altered in cancer and have added significantly to our armamentarium in order to prolong patient survival and minimizing drug toxicity. Among 34 molecularly targeted drugs approved by U.S. Food and Drug Administration (FDA) for treatment of various cancers since 1998 three targeted therapies have been approved for treatment of lung cancer (gefitinib in 2002, erlotinib in 2003, and bevacizumab in 2006).This review focuses on the targeted therapies in lung cancer, the molecular biomarkers that help identify patients that will benefit for these targeted therapies, describes the basic molecular biology principles and selected molecular diagnostic techniques and the pathological features correlated with molecular abnormalities in lung cancer. Lastly, new molecular abnormalities described in lung cancer that are predictive to novel promising targeted agents in various phases of clinical trials are discussed.

Citing Articles

Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975-2022 with insights on the impact of COVID-19.

Yamamoto H, Shirasawa M, Naoki K Int J Clin Oncol. 2025; 30(2):199-209.

PMID: 39821472 DOI: 10.1007/s10147-025-02695-4.

Epidemiological Study of Return to Work and Mortality in Lung Cancer Survivors.

Yang Z, Lai C, Ho C, Wang C Int J Environ Res Public Health. 2022; 19(1).

PMID: 35010569 PMC: 8744858. DOI: 10.3390/ijerph19010309.

Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines.

Konkolova E, Hudacova M, Hamulakova S, Jendzelovsky R, Vargova J, Sevc J Molecules. 2021; 26(4).

PMID: 33672694 PMC: 7924348. DOI: 10.3390/molecules26041133.

Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1.

Sippel T, Johnson A, Li H, Hanson D, Nguyen T, Bullock B Mol Cancer Res. 2019; 17(8):1748-1758.

PMID: 31088909 PMC: 7439607. DOI: 10.1158/1541-7786.MCR-19-0236.

MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway.

Chen W, Zhao W, Zhang L, Wang L, Wang J, Wan Z Oncotarget. 2017; 8(55):94317-94329.

PMID: 29212230 PMC: 5706876. DOI: 10.18632/oncotarget.21693.

References

Mino-Kenudson M, Chirieac L, Law K, Hornick J, Lindeman N, Mark E . A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16(5):1561-71. PMC: 2831135. DOI: 10.1158/1078-0432.CCR-09-2845. View

Lamant L, Meggetto F, Al Saati T, Brugieres L, de Paillerets B, Dastugue N . High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996; 87(1):284-91. View

Jackman D, Yeap B, Sequist L, Lindeman N, Holmes A, Joshi V . Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(13):3908-14. DOI: 10.1158/1078-0432.CCR-06-0462. View

Sasaki H, Shimizu S, Endo K, Takada M, Kawahara M, Tanaka H . EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 2005; 118(1):180-4. DOI: 10.1002/ijc.21301. View

Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(25):5892-9. DOI: 10.1200/JCO.2005.02.840. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

West H, Franklin W, McCoy J, Gumerlock P, Vance R, Lau D . Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006; 24(12):1807-13. DOI: 10.1200/JCO.2005.04.9890. View

Varella-Garcia M . Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol. 2006; 1:19. PMC: 1560164. DOI: 10.1186/1746-1596-1-19. View

Hampton T . Lung cancer trials probe effects of maintenance therapy, targeted agents. JAMA. 2009; 302(6):616, 618. DOI: 10.1001/jama.2009.1118. View

10.

Brevet M, Arcila M, Ladanyi M . Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010; 12(2):169-76. PMC: 2871723. DOI: 10.2353/jmoldx.2010.090140. View

11.

Ahrendt S, Decker P, Alawi E, Zhu Yr Y, Sanchez-Cespedes M, Yang S . Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001; 92(6):1525-30. DOI: 10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h. View

12.

Zhu C, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N . Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26(26):4268-75. DOI: 10.1200/JCO.2007.14.8924. View

13.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

14.

Pao W, Ladanyi M . Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007; 13(17):4954-5. DOI: 10.1158/1078-0432.CCR-07-1387. View

15.

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H . Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6):1190-203. DOI: 10.1016/j.cell.2007.11.025. View

16.

Motoi N, Szoke J, Riely G, Seshan V, Kris M, Rusch V . Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32(6):810-27. DOI: 10.1097/PAS.0b013e31815cb162. View

17.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

18.

Eberhard D, Johnson B, Amler L, Goddard A, Heldens S, Herbst R . Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-9. DOI: 10.1200/JCO.2005.02.857. View

19.

Marks J, Broderick S, Zhou Q, Chitale D, Li A, Zakowski M . Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008; 3(2):111-6. DOI: 10.1097/JTO.0b013e318160c607. View

20.

Ellis L, Hicklin D . Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res. 2009; 15(24):7471-7478. DOI: 10.1158/1078-0432.CCR-09-1070. View